Although the introduction of selective v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors has been a major advance in treatment of metastatic melanoma, approximately 50% of patients have limited responses including stabilization of disease or no response at all. This study aims to identify a novel means of overcoming resistance of melanoma to killing by BRAF inhibitors. We examined the influence of the BH3-mimetic ABT-737 on induction of apoptosis by the selective BRAF inhibitor PLX4720 in melanoma cells with or without BRAF V600E mutation. Included were cell lines established from four patients before and during treatment with selective BRAF inhibitors and 3D spheroids derived from these cell lines. Cell lines with no or low sensitivity to PLX4720 underwent synergistic increases and increased rates of apoptosis when combined with ABT-737. This degree of synergism was not seen in cell lines without BRAF V600E mutations. Apoptosis was mediated through the mitochondrial pathway and was due in part to upregulation of Bim as shown by inhibition of apoptosis following small interfering RNA knockdown of Bim. Similar effects were seen in cell lines established from patients prior to treatment but not in lines from patients clinically resistant to the selective BRAF inhibitors and in 3D spheroids derived from these cell lines. These results suggest that combination of selective BRAF inhibitors with ABT-737 or the related orally available compound ABT-263 may increase the degree and rate of responses in previously untreated patients with V600E melanoma but not in those with acquired resistance to these agents.
Introduction
The introduction of selective BRAF inhibitors has been a major advance in the treatment of metastatic melanoma that has V600 mutations in the BRAF protein (1) (2) (3) . One of these drugs, vemurafenib (PLX 4032/ RG7204/Zelboraf) has now been evaluated in phase II (4) and III (5) trials and shown to significantly prolong both progression free survival and overall survival compared with standard chemotherapy with dacarbazine (DTIC). The drug GSK2118436 (dabrafenib) is also highly selective for the mutated forms of BRAF. In phase III studies, 53% of 187 patients had confirmed partial responses by response evaluation criteria in solid tumors (RECIST) criteria (6) .
Although these results are impressive, they show that the treatment has two limitations. One is the failure to induce significant responses in approximately 50% of patients including no response at all in approximately 10% of patients (5, 7) . The second is the development of acquired resistance in the majority of patients over time (1, 8, 9) . The mechanisms involved in resistance to the drugs include a switch from BRAF to RAF proto-oncogene serine/threonine-protein kinase (CRAF) signaling (10) , activating mutations in NRAS (11) or activation of mitogen-activated protein kinase kinase (MEK) by alternate kinases such as COT (12) . We have also reported that extracellular signal-regulated kinase (ERK) can be activated by cross talk from the AkT pathway independent of MEK (13) . In addition, dimerization of an aberrantly spliced form of BRAF that was resistant to vemurafenib was identified in 6 of 19 patients with acquired resistance to vemurafenib (14) . Activation of alternate pathways, which bypass the MEK/ERK pathway, has also evolved as a major mechanism of resistance. Studies by Nazarian et al. (2010) (11) identified one subset of melanoma cells with upregulation of the platelet-derived growth factor receptor B (PDGFRB) that appeared to bypass the MEK/ERK pathway (9) (10) (11) . These results were applicable to 5 of 12 patients who developed resistance to treatment with PLX4032. Increased expression of insulin-like growth factor 1R was associated with acquired resistance to vemurafenib in two of five postrelapse patient samples (15) . The mechanisms underlying constitutive resistance appear similar to those of acquired resistance (16) and include activating mutations of NRAS, copy number gains of regions coding for MAP3K8(COT) and activation of RAS or alternate pathways by activation of platelet-derived growth factor receptor B or insulin-like growth factor 1R (8) . Stromal cell production of hepatocyte growth factor is yet another cause of resistance to selective BRAF inhibitors (17) .
We and others have shown that selective BRAF inhibitors can not only inhibit cell division in G 1 but can also induce apoptosis in a proportion of melanoma with BRAF V600E mutations (13, (18) (19) (20) . We have, therefore, argued that induction of apoptosis by the BRAF inhibitors may be needed to increase the proportion of patients undergoing clinical responses and their durability (21) . The approach explored in this study was to use agents that inhibit the antiapoptotic proteins such as those of the Bcl-2 family. The BH3-mimetic ABT-737 is one such agent that selectively inhibits Bcl-2, Bcl-XL and Bcl-W, and the related orally available compound ABT-263 is known to have clinical activity against some forms of leukemia, lymphoma and small cell lung carcinoma (22, 23) . It has, however, limited activity as a single agent against melanoma due to its relative ineffectiveness against Mcl-1, which is a key inhibitor of apoptosis in melanoma (23) (24) (25) (26) (27) . Given that mitogen-activated protein kinase pathway inhibitors downregulate Mcl-1 in melanoma (28) , there was reason to believe that this combination may increase the effectiveness of the BRAF inhibitors against melanoma and, therefore, supplement ongoing efforts in the translation of these agents into more effective treatment options.
In this study, we have examined the effectiveness of the combination of the selective BRAF inhibitor PLX4720 plus ABT-737 against a range of BRAF V600E-positive melanoma cell lines including those with little or no sensitivity to PLX4720 in apoptosis assays. The sensitivity to PLX4720 and ABT-737 was assayed in 2D and 3D models in vitro. To increase the relevance to future clinical studies, we included four pairs of cell lines established from patients before and during treatment with selective BRAF inhibitors. the phase II GSK study of treatment with GSK 2118436. These studies were approved by the Hunter and New England Research Ethics Committee.
Materials
ABT-737 was provided by Abbott Laboratories and dissolved in dimethyl sulfoxide to a stock solution of 20 mM. PLX4720 was provided by Plexxikon Inc (Berkeley, CA) and dissolved in dimethyl sulfoxide to a stock solution of 4 mM. U0126 was provided by Promega (Madison, WI). For treatment of melanoma cells, ABT-737 and PLX4720 were diluted in Dulbecco's modified Eagle's medium containing 5% fetal calf serum to a final dimethyl sulfoxide concentration of 0.1%. The mouse monoclonal antibodies against Bcl-2, Bcl-XL and Mcl-1 and the rabbit polyclonal antibodies against pERK were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal antibodies against poly (ADP ribose) polymerase (PARP) were obtained from BD Pharmingen (North Ryde, NSW, Australia). Rabbit polyclonal antibodies against Bim were from Imgenex (San Diego, CA). The rabbit polyclonal antibodies against caspase-3 and -9 were obtained from Stressgen (Victoria, British Columbia, Canada). The rabbit polyclonal antibodies against (PUMA) p53 upregulated modulator of apoptosis and the mouse monoclonal antibodies against ERK were from Cell Signalling Technology (Beverly, MA). Propidium iodide and G418 was purchased from Sigma-Aldrich (Castle Hill, NSW, Australia).
Melanoma 3D-spheroid assays
Melanoma spheroids were prepared as described (31, 32) . This model mimics in vivo tumor architecture and microenvironment and is used for investigating growth, invasion and viability of melanoma cells (18, 20, 27, 33, 34) . Briefly, 200 µl of melanoma cell suspension (25 000 cells/ml) was overlaid on top of hard (1.5%) agar. Plates were incubated for 72 h until 3D spheroids have formed. The resulting spheroids were then harvested and transferred to a falcon tube and allowed to settle. The medium was aspirated and replaced by a buffered collagen suspension, containing bovine collagen type I (Cultrex) at a final concentration of 2.1 mg/ml in Eagle's Minimal Essential Medium (Sigma-Aldrich), 1.7 mM l-glutamine (Sigma-Aldrich) and 10% fetal calf serum (Sigma-Aldrich) adjusted to pH 7 using 7.5% sodium bicarbonate (Sigma-Aldrich). Then, 24-well plates were overlaid with 200 µl/well acellular collagen, which was allowed to set. About 300 µl/well of spheroid/collagen mixture was added to the acellular collagen layer and allowed to polymerize. Finally, normal melanoma medium was added. Drug treatment was performed as indicated. Experiments were finalized by washing thrice with phosphate-buffered saline (PBS) and incubation with 2 mM ethidium homodimer-I (Invitrogen) in PBS for 1 h and visualized using an inverted Nikon-T i fluorescence microscope.
Analysis of cell death
Quantitation of apoptotic cells by measurement of sub-G 1 DNA content using the propidium iodide method was carried out as described elsewhere (29) . Analysis of propidium iodide-stained cells was carried out using a Becton Dickinson (Mountain View, CA) FACSCanto flow cytometer.
Analysis of synergy
Synergistic interaction between agents was analyzed using the median effect principle established by Chou and Talalay (35) . CalcuSyn software was used to generate Fa-CI isobologram plots (Biosoft, Cambridge, UK; www.biosoft.com, last accessed 29/10/2012).
Measurement of mitochondrial membrane potential
Melanoma cells were seeded at 1 × 10 5 cells per well in 24-well plates and allowed to reach exponential growth for 24 h before treatment. Changes in mitochondrial membrane potential (∆Ψ m ) were studied by staining the cells with the cationic dye, JC-1, according to the manufacturer's instructions (Molecular Probes, Eugene, OR) as described previously (36) .
Western blotting
Western blot analysis was carried out as described previously (24) . Labeled bands were detected by Immun-Star horseradish peroxidase chemiluminescence kit (Bio-Rad, Regents Park, NSW, Australia), and images were captured with the Fujifilm LAS-4000 image system (Fujifilm, Brookvale, NSW, Australia).
Small interfering RNA knockdown
The small interfering RNA (siRNA) constructs used were obtained as the non-targeting siRNA control, siGENOME Non-Targeting siRNA Pool #1 (D-001206- [13] [14] [15] [16] [17] [18] [19] [20] and the siGENOME SMARTpool Bim/BCL2L11 (M-004383-02-0010) (Dharmacon, Lafayette, CO). Transfection of siRNA pools was carried out as described previously (28) .
Stable overexpression
Cell lines stably overexpressing Mcl-1 were generated. Cells were transfected for 6 h with p3XFLAG-CMV-10 vector alone or with vector-containing full-length Mcl-1 complementary DNA (cDNA), kindly provided by Dr Xiaodong Wang (Howard Hughes Medical Institute, Dallas, TX), before addition of fresh media for a further 24 h. Cells were then selected with 1500 µg/ ml G418, resistant colonies cultured and Mcl-1 overexpression confirmed by western blotting.
Immunoprecipitation
Immunoprecipitation of selected proteins was performed using TrueBlot AntiMouse Ig IP beads (eBioscience, SA, Australia) as per manufacturer's instructions. Briefly, 30 µl of beads were added to 500 µl cold PBS and 5 µg of either Mcl-1 or mouse IgG 1 (negative control) antibody and rotated at 4°C for 2 h before washing three times in cold lysis buffer and isolation of beads by centrifugation. About 1 × 10 7 cells were treated as indicated, collected by trypsinization and protein isolated in 1ml lysis buffer. Four hundred microliters of each sample, containing equal amounts of protein, were precleared by addition of 30 µl fresh beads and rotated at 4°C for 30 min before 4°C centrifugation at 10 000g. Supernatant was added directly to antibody-conjugated beads and rotated at 4°C for 2 h before 4°C centrifugation at 10 000g and washing three times in cold lysis buffer, followed by once in cold PBS. About 30 µl of reducing sodium dodecyl sulfate (SDS) loading buffer was added to beads, boiled for 5 min, centrifuged and the supernatant subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Results

ABT-737 sensitizes melanoma cells to apoptosis induced by PLX4720
To investigate the apoptosis-inducing potential of a combination of PLX4720 and ABT-737, we treated a panel of melanoma cell lines with varied BRAF, CDK4 and NRAS mutational status. Cells were collected and sub-G 1 DNA content was measured using the propidium iodide method 24 h following treatment. Figure 1A shows that, in combination, 5 µM each of PLX4720 and ABT-737 co-operated to induce markedly higher levels of cell death than either drug alone. This was particularly evident in cell lines with both BRAF and CDK4 mutations. It was also evident that cell lines that were constitutively resistant to the BRAF inhibitor became markedly sensitive in the presence of ABT-737. The NRAS mutants and the wild-type ME1007 were not generally more sensitive to the combination except for the Mel-RM line, which showed a significant increase in apoptosis when exposed to the combination. Some synergy was observed in cell lines containing wild-type BRAF; however, total cell death was less than that in cells harboring the mutation. Synergistic induction of apoptosis also occurred following treatment with lower doses of the agents (data not shown).
Given the dramatic synergistic effect in a 2D system, we examined the efficacy of this combination in a 3D-spheroid model, which mimics tumor architecture and microenvironment (31, 32) and has been used for investigating drug effects on growth, invasion and viability of melanoma cells by a number of authors (18, 20, 27, 33, 34) . The 3D culture system was reported to closely mimic results of studies in vivo (32) . Spheroids derived from Mel-RMu and Sk-Mel-28 cells were strongly sensitized to PLX4720 following treatment with ABT-737 for 24 h, indicated by increased staining of dead cells by ethidium homodimer-1 compared with control spheroids ( Figure 1B ). IgR3 cells did not form spheroids and showed comparatively lower increase in sensitivity, whereas the combination had no effect in the ME4405 spheroids.
Further evidence of the potential clinical relevance of the increased apoptosis shown with the combination came from colony formation studies of the time taken to develop acquired resistance to PLX4720. As shown in Jiang et al. (2011) (13) , culture of Mel-RMu in PLX4720 (10 µM) for 21 days resulted in the outgrowth of colonies resistant to PLX4720. However, when PLX4720 was combined with ABT-737, no outgrowth of colonies was evident for periods in excess of 8 weeks (data not shown).
A formal test of synergy was carried out by dose titrations against two sensitive BRAF mutant cell lines, Mel-RMu and Sk-Mel-28, with proportionally increasing doses from 1.25 to 10 µM. As shown in Figure 1C , significant sensitization occurred from the lowest combination tested. Synergy was tested between the agents by generation of Fa-CI isobologram plots using the Chou and Talalay method (35) .
ABT-737 sensitizes melanoma to BRAF inhibition
Briefly, the combination index (CI) is a statistical measure of synergy derived from dose-response values for single agent versus combination treatment. Data points close to 1 on the y-axis (indicated by dotted line) suggest an additive effect, with points >1 representing inhibition and <1 representing synergy. CI values approaching 0 indicate strong synergy. Figure 1D shows significant synergy in all combinations tested between the agents in both cell lines. Furthermore, particularly strong synergy was demonstrated in other BRAF V600E/CDK4 R24C cell lines, as indicated by CI values lower than 0.1 ( Figure 1A) .
To confirm induction of apoptosis by the agents, we treated MelRMu and Sk-Mel-28 cells with 3 µM of each drug alone and in combination for 6 and 16 h, and examined activation of caspase-3 and its substrate, PARP, by western blotting. Figure 1E shows strong cleavage of caspase-3 and PARP (classic indicators of induction of ABT-737 sensitizes melanoma to BRAF inhibition apoptosis) at 16 h with the combination of agents, whereas very few cleavage products were detected following treatment with individual agents.
As the addition of MEK inhibitors has shown some promise in overcoming the development of resistance to BRAF inhibitors (37), we investigated whether ABT-737 would further increase the efficacy of this combination. Although Mel-RMu, Sk-Mel-28 and IgR3 cells were sensitive to the addition of ABT-737 to either PLX4720 or the MEK inhibitor, U0126, cell death was greater in cells treated with the combination of three agents (Supplementary Figure 1 , available at Carcinogenesis Online). Although little effect was seen in cells exposed to only PLX4720 and U0126, extended treatment results in a synergistic effect (data not shown).
Treatment with PLX4720 and ABT-737 induces changes in Bcl-2 family protein expression
In order to confirm activity specific to the MEK/ERK pathway, we treated sensitive Mel-RMu and Sk-Mel-28 cells, along with relatively insensitive IgR3, for short periods with PLX4720, ABT-737 or the combination. Protein expression levels were then determined by western blotting. As shown in Figure 2A , rapid ERK dephosphorylation occurs following treatment with PLX4720 in all cell lines. Some phospho-ERK recovery is evident at 6 h. Dephosphorylation of ERK was coincident with that of Bim and subsequent upregulation of Bim expression. Interestingly, ABT-737 had varying effects on phosphorylation of ERK, with an initial decrease in Mel-RMu, no effect in Sk-Mel-28 and gradual increase in IgR3. Treatment with the combination initially reduced ERK phosphorylation in Sk-Mel-28 and IgR3 cells, but surprisingly this was not observed in Mel-RMu.
To determine the mechanism behind induction of apoptosis by the combination of agents, we examined changes in pro-and antiapoptotic protein expression in the above cell lines. Cells were exposed to 3 µM of either PLX4720, ABT-737 or the combination for 6 or 16 h; the lower dose and time were chosen to better represent biological effects and avoid potential artifacts arising from massive cell death, and protein expression levels were determined by western blotting.
The most dramatic change in Bcl-2 family proteins was observed in Bim following treatment of the sensitive cell lines with PLX4720. As shown in Figure 2B , dephosphorylation and subsequent increase of Bim occurred at 6 h in Mel-RMu and Sk-Mel-28 cells, increasing to 16 h. Interestingly, in the resistant line, IgR3, Bim induction was comparatively less in PLX4720-treated cells (Figure 2A) . No dephosphorylation of Bim EL or change in total Bim expression was detected in wild-type Mel-RM and ME1007 cell lines (data not shown). Furthermore, total Bim levels in Mel-RMu cells treated with the combination was no higher than in those treated with PLX4720 alone; however, expression was still greater than in untreated cells and corresponded to the dephosphorylated form of the protein. The reduction in Mcl-1 levels may be predominately due to decreases in transcription as shown by the decrease in messenger RNA levels after treatment with PLX4720 (data not shown).
We investigated whether the increased expression of Bim following treatment resulted in greater association of Bim with Mcl-1. We performed immunoprecipitation in cells treated with PLX4720 to determine the interaction between the proteins. Sensitive Mel-RMu and Sk-Mel-28 cells were treated for 24 h with 3 µM PLX4720 and subjected to immunoprecipitation of Mcl-1, followed by reducing SDS-PAGE and detection of Bim by western blotting. Figure 2C 
Combination of PLX4720 and ABT-737 activates the intrinsic apoptotic pathway
It is currently understood that under resting conditions, the integrity of the mitochondrial outer membrane is protected by antiapoptotic Bcl-2 family proteins through sequestration of proapoptotic Bax and Bak (38, 39) . In response to apoptotic signaling, greater interaction between pro-and anti-apoptotic Bcl-2 family proteins releases Bax and Bak, allowing their dimerization at the mitochondrial membrane and formation of pores for the release of apoptogenic factors. As activation of the mitochondrial death pathway is known to be critical for ABT-737-induced apoptosis (40), we investigated whether the combination of the drugs enhanced depolarization of the mitochondria. The BRAF V600E cell lines Mel-RMu, Sk-Mel-28 and IgR3 were treated with either PLX4720 or ABT-737 alone and in combination, and changes in mitochondrial membrane potential (∆Ψ m ) was assessed. Figure 3A shows that although 3 µM of either drug alone was insufficient to induce significant depolarization of the mitochondrial outer membrane, a large decrease in potential occurred 16 h following treatment with the combination of agents in the sensitive cell lines, but not in the resistant line, IgR3. Co-treatment with 10 µM of each compound induced similar levels of ∆Ψ m as early as 6 h and was significantly higher after 16 h ( Figure 3B ). Additionally, cleavage of caspase-9 was detected at 16 h in cells treated with the combination, confirming activation of the mitochondrial apoptotic pathway ( Figure 3C ). Strong, dose-and timedependent caspase-9 cleavage was also observed in the other sensitive line, Sk-Mel-28; however, little effect was seen in the resistant line, IgR3, suggesting the importance of the intrinsic apoptotic pathway in combination-induced apoptosis (data not shown).
To confirm the role of caspases in combination-induced apoptosis, we pretreated cells with the pan-caspase inhibitor, z-VAD-fmk for 1 h prior to addition of 3 µM of each agent. Figure 3D shows that apoptosis was caspase-dependent, with nearly total inhibition of cell death induced by the combination.
Bim knockdown protects against PLX4720-and ABT-737-induced apoptosis
Due to the dramatic increase in Bim expression following treatment with PLX4720 and the involvement of the mitochondria in combination-induced apoptosis, the role of Bim in the induction of cell death was examined by siRNA knockdown of Bim in the sensitive Sk-Mel-28 and Mel-RMu cell lines and the resistant IgR3 line. Figure 4A shows effective reduction of Bim and this persisted following treatment with the combination of drugs. Knockdown was specific for Bim, as shown by unaffected expression of Bcl-2 in cells subjected to Bim siRNA. Levels of the BH3 protein PUMA were also unaffected by Bim siRNA (results not shown). The apoptosis assays shown in Figure 4B data support the view that the reduction in Mcl-1 levels seen in nontransfected cells were probably to contribute to the synergistic effect of the combined agents.
The combination of PLX4720 and ABT-737 is not effective against selective BRAF inhibitor-resistant cell lines
Given that melanoma lines that were constitutively resistant to PLX4720 were sensitive to the combination with ABT-737, we investigated whether the combination would also be effective against cell lines established from patients with acquired resistance to vemurafenib. As shown in Figure 5A , 24 h exposure of pretreatment samples to PLX4720 and ABT-737 strongly arrested proliferation and induced cell death, with a large increase in G 1 and sub-G 1 DNA content. However, there was little or no increase in sub-G 1 fraction in the cell lines established from vemurafenib-resistant patients ( Figure 5A ). Pretreatment of Patient 1 and Patient 3 cells were particularly sensitive to the combination treatment, as shown in Figure 5B ; however, addition of ABT-737 was insufficient to reverse resistance to apoptosis induced the BRAF inhibitor in post-treatment samples. Similar results were found in studies on a further two patients who had been treated with vemurafenib and GSK2118436 (data not shown).
Studies on Patient 3 cells in 3D-spheroid models confirmed the 2D data ( Figure 5C ), where significant increase of dead cells was evident in spheroids derived from pretreatment cells treated with ABT-737 and PLX4032 combined, but not in those from post-treatment cells. Interestingly, the post-treatment cells did not form spheroids.
The western blot studies shown in Figure 5D for Patient 1 show an increase in Mcl-1 levels, which may have accounted in part for resistance to the combination of PLX4720 and ABT-737 in this line. The western blot studies on the vemurafenib-resistant line from Patient 3 show that Bim isoforms were less evident compared with pretreatment samples. Bcl-2 levels were also higher in this line, which may have contributed to its resistance. PARP cleavage was also not evident in the resistant lines. We have previously reported (41) that the concentrations of PLX4720 used in this study were sufficient to inhibit phosphorylation of ERK in the pretreatment lines from Patient 3 but only partially inhibited pERK in the resistant lines established from this patient. In Patient 1, the inhibition of pERK was minimal in the line established pretreatment, and there was no inhibition in the line established during progression of the disease. The basis for the resistance to this pathway in this line remains under study.
Discussion
The above results demonstrate that combining a selective BRAF inhibitor with the BH3-mimetic ABT-737 (or the related orally available compound ABT-263) may greatly increase the efficacy of selective BRAF inhibitors against BRAF V600E-mutated melanoma, by employing complementary mechanisms in order to overcome antiapoptotic Bcl-2 family protein-mediated resistance to killing. The combination was particularly impressive when applied to 3D-spheroid models, which suggests that the combination may also be effective in vivo (32) . Further confirmation of this will require studies in xenograft models that take into account the effects of other cell types in the microenvironment. Induction of apoptosis appeared higher in melanoma cell lines with both BRAF V600E and CDK4 R24C mutations but whether the latter mutation was playing a functional role in this sensitivity is not clear. Although the degree of synergism was marked in most of the BRAF V600E cell lines, the absolute level of apoptosis remained relatively low in some of the lines such as IgR3.
These comments aside, it is clear that BRAF V600E melanoma cell lines with high resistance to PLX4720 alone became highly sensitive when treated in vitro with the combination. Induction of apoptosis was relatively rapid compared with that seen with PLX4720 alone (13, 19) , as evidenced by cleavage of caspase-3 and its substrate PARP as early as 16 h. Apoptosis was caspase-dependent and involved activation of the intrinsic apoptotic pathway as shown by significant reduction in mitochondrial membrane potential and by processing of caspase-9. In addition, significant dephosphorylation of ERK and Bim, along with subsequent increase in expression of Bim EL, was shown to occur rapidly following treatment with PLX4720 in sensitive BRAF V600E-mutated cell lines, but not in resistant mutant and wild-type lines. In effect, the addition of ABT-737 to the selective BRAF inhibitor changed the slow, largely caspase-independent apoptosis seen in response to the MEK inhibitor UO126 reported previously (36) to a more rapid caspase-dependent mechanism.
The focus on Bim in these studies follows results from previous studies showing that direct phosphorylation of Bim by ERK1/2 regulates its expression and proapoptotic activity, targeting Bim for proteasomal degradation (42) and disrupting its direct association with Mcl-1 and Bcl-XL (43) . Inhibition of ERK subsequently alleviates Bim phosphorylation, resulting in its upregulation. Others have demonstrated the importance of Bim upregulation for apoptosis induced by inhibiting elements of the Ras/Raf/MEK/ERK pathway (36, 44) . We have previously reported the critical role of Bim and its isoforms in PLX4720-induced apoptosis in melanoma cells (19) . Inhibition of MEK, downstream of BRAF, has also been identified as effective in sensitizing cells to BH3 mimetics in a Bim-dependent manner (44) .
Given that we and others (23, 26, 27) have shown that ABT-737 is ineffective in antagonizing the antiapoptotic protein Mcl-1 and that BRAF (19) and MEK/ERK (36) inhibition may be associated with reduced levels of Mcl-1, it was considered most probably that the synergism seen in these studies was due to upregulation of Bim by PLX4720 (19) and neutralization of Bcl-2 and Bcl-XL by ABT-737 combined with downregulation of Mcl-1, 'priming' cells to induction of apoptosis. The downregulation of Mcl-1 was predominantly due to reduction in messenger RNA levels, most probably due to downregulation of the Ets-1 transcription factor, which is a known target of the MEK/ ERK pathway and known to regulate Mcl-1 (45) . Concurrent inhibition of Bcl-2 and Bcl-XL by ABT-737 would increase the amount of 'free' Bim available for inhibition of Mcl-1, subsequently overcoming resistance to the compound. This hypothesis was supported by a strong correlation between dramatically increased Bim levels and induction of apoptosis as shown in the Mel-RMu and Sk-Mel-28 lines and low levels in the insensitive IgR3 line. Although Bim levels in Sk-Mel-28 cells treated with the combination were not increased above the levels induced by PLX4720 alone, total Bim expression was reduced in MelRMu cells treated with both agents, perhaps due to some restoration of phosphorylated ERK. Nevertheless, expression of active, dephosphorylated Bim remained higher than in untreated cells and appeared sufficient to sensitize cells to apoptosis. Moreover, siRNA silencing of Bim resulted in significant reduction in apoptosis mediated by the combination, along with moderate inhibition of apoptosis following overexpression of Mcl-1. Immunoprecipitation studies also showed a greater association of Bim with Mcl-1 consistent with neutralization of its antiapoptotic effects.
Despite the strong evidence for the important role of Bim and Mcl-1 in the synergistic induction of apoptosis, there was considerable cell line-dependent variation in phosphorylation of ERK, Bim and Mcl-1 expression. In some instances, the actual levels of these factors were not predictive of the synergistic response so that other identified factors may be involved. We investigated whether activation of adenosine monophosphate-dependent kinase (AMPK) may be involved as ABT-737 was reported to induce activating phosphorylation of AMPK and inhibition of mammalian target of rapamycin (46) . Previous studies have shown that activation of AMPK may assist in activation of Bim (47) and induce apoptosis in melanoma cells. AMPK activity was also reported to be suppressed in melanoma cells harboring the BRAF V600E mutation, inhibition of which resulted in AMPK induction (48) . However, we did not see a significant effect on induction of AMPK in this study (data not shown) making it unlikely as a contributing factor in induction of apoptosis.
Extension of the studies to BRAF V600E tumor samples obtained from patients during treatment with selective BRAF inhibitors showed that synergistic induction of apoptosis occurred in the cell lines established pretreatment. The combination also showed impressive efficacy in 3D cultures in vitro, which mimic the tumor microenvironment in vivo and suggest its potential for treatment in the clinic. However, sensitization appeared to be lost in cell lines derived from mutation-positive tumors of the same patients who had developed resistance to the BRAF inhibitors. These results if translatable to the clinic suggest that the combination of a BRAF inhibitor and BH3 mimetic is probably to be most effective when given as primary treatment and is unlikely to reverse acquired resistance to vemurafenib. Despite this limitation, the use of this combination might be expected to increase the percentage and the degree of response rates in patients compared with that seen in patients treated with the selective BRAF inhibitors alone (1) .
The results from this study add to the increasing number of studies showing that treatment with ABT-737 is most effective when combined with other agents. These include chemotherapy (49, 50) , temozolomide (51), flavopiridol (27) and immunotoxins (52) . The concentration levels of ABT-737 used in these studies were equivalent or less than the serum concentrations of 4-7 µM of ABT-263 recorded in phase 1 studies (53) . Serum levels of 7 µM were also reported in studies on xenografts (54) . Similarly, the concentrations of PLX4720 appear well below the 80 µM concentrations recorded in phase 1 studies of PLX4032 (vemurafenib (1)). The only combination that may be deleterious is with immunotherapy as it was reported that ABT-263 induced unexpected immunoregulatory effects due to increased apoptosis of lymphocytes (55) . In conclusion, this study suggest that the combination of selective BRAF inhibitors with ABT-263 may be effective as first line therapy in patients with metastatic melanoma in increasing the response rates to selective BRAF inhibitors. Both drugs (including that of mild thrombocytopenia with ABT-263) have been shown to have acceptable safety profiles, which should facilitate conduct of phase 1 trials in patients with metastatic melanoma.
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